At NINGBO INNO PHARMCHEM CO.,LTD., we understand that the effectiveness of an API like Meloxicam is deeply tied to its pharmacokinetic profile. Understanding how the body processes Meloxicam—its absorption, distribution, metabolism, and excretion (ADME)—is crucial for optimizing its therapeutic use and appreciating its pharmacological behavior. This knowledge is vital for pharmaceutical companies when they decide to buy Meloxicam.

Meloxicam exhibits good oral bioavailability, with absorption generally occurring rapidly after administration. When taken orally, it reaches peak plasma concentrations typically within 4 to 5 hours. The presence of food, particularly high-fat meals, can influence absorption rates by increasing peak drug levels, though overall absorption remains largely unaffected. This pharmacokinetic characteristic is important to consider when discussing Meloxicam dosage and timing with patients. The quality of the Meloxicam purchased directly impacts these absorption characteristics.

Once absorbed, Meloxicam is extensively bound to plasma proteins, primarily albumin, to about 99.4%. This high protein binding affects its distribution throughout the body. The elimination half-life of Meloxicam is approximately 15 to 20 hours, allowing for once-daily dosing for many patients, which enhances convenience and adherence. This prolonged half-life contributes to its sustained anti-inflammatory effect.

Metabolism of Meloxicam primarily occurs in the liver, mainly through the cytochrome P450 enzymes CYP2C9 and to a lesser extent CYP3A4. It is metabolized into four inactive metabolites. The extensive metabolism means that individuals with impaired liver function or those taking other medications that affect these CYP enzymes may require dosage adjustments. Understanding these metabolic pathways is critical for drug development and safety assessments.

Excretion of Meloxicam and its metabolites occurs equally in urine and feces. A small fraction of the unchanged drug is found in both urine and feces. The drug's pharmacokinetic properties, including its relatively long half-life and extensive protein binding, contribute to its efficacy in treating chronic inflammatory conditions. For pharmaceutical manufacturers seeking to purchase Meloxicam, partnering with NINGBO INNO PHARMCHEM CO.,LTD. ensures access to a high-purity API with well-defined pharmacokinetic properties, supporting the development of safe and effective medications.